

RECEIVED
JAN 08 2003
TECH CENTER 1600/2900

Sheet 1 of 4

Form PTO-1449
(Rev. 2-88)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
6460-41

APPLICATION NO.
10/075,823

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

APPLICANT
Debinski et al.

FILING DATE
February 12, 2002

GROUP
1644

U.S. PATENT DOCUMENTS

EXAMINER'S INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Patt		Goldman et al., "Epidermal Growth Factor Stimulates Vascular Endothelial Growth Factor Production by Human Malignant Glioma Cells: A Model of Glioblastoma Multiforme Pathophysiology," Molecular Biology of the Cell, 4: 121-133, 1993
↓		Kerbel et al., "Establishing a Link between Oncogenes and Tumor Angiogenesis," Molecular Medicine, 4: 286-295, 1998
		Orlandini et al., "Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family," Proc. Natl. Acad. Sci. USA, 93: 11675-11680, 1996
		Achen et al., "Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)," Proc. Natl. Acad. Sci. USA, 95: 548-553, 1998
		Marconcini et al., "c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro," Proc. Natl. Acad. Sci. USA, 96: 9671-9676, 1999
		Mintz A. and W. Debinski, "Cancer Genetics/Epigenetics and the X Chromosome: Possible New Links for Malignant Glioma Pathogenesis and Immune-Based Therapies," Critical Reviews in Oncogenesis, 11: 77-95, 2000
EXAMINER		DATE CONSIDERED 11/17/04

* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449
(Rev. 2-88)

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
6460-41

APPLICATION NO.
10/075,823

APPLICANT
Debinski et al.

FILING DATE
February 12, 2002

GROUP

RECEIVED

JAN 08 2003

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS


EXAMINER'S INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

PNT ↓		Achen et al., "Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3," Eur. J. Biochem. 267: 2505-2515, 2000
		Stacker et al., "Biosynthesis of Vascular Endothelial Growth Factor-D Involves Proteolytic Processing Which Generates Non-covalent Homodimers," The Journal of Biological Chemistry, 274: 32127-32136, 1999
		Halfter et al., "Growth inhibition of newly established human glioma cell lines by leukemia inhibitory factor," Journal of Neuro Oncology, 39: 1-18, 1998
		Bergers et al., "Transcriptional Activation of the <i>fra-1</i> Gene by AP-1 Is Mediated by Regulatory Sequences in the First Intron," Molecular and Cellular Biology, 15: 3748-3758, 1995
		Tulchinsky, E., "Fos family members: regulation, structure and role in oncogenic transformation," Histol Histopathol, 15: 921-928, 2000
		Lilja et al., "ABNORMAL EXPRESSION OF OSM, CNTF AND LIF IN HUMAN BRAIN TUMORS," Neuro-Oncology, 2: S22
EXAMINER		DATE CONSIDERED 11/17/04
* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		



Sheet 4 of 4

JC102-1449
(Rev. 2-88)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
6460-41APPLICATION NO.
10/075,823INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

APPLICANT
Debinski et al.FILING DATE
February 12, 2002

GROUP

RECEIVED
JAN 08 2003
TECH CENTER 1000/2900

U.S. PATENT DOCUMENTS


EXAMINER'S INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Pst ↓		Strawn et al., "Flk-1 as a Target for Tumor Growth Inhibition," Cancer Research, 56: 3540-3545, 1996
		Prewett et al., "Antivascular Endothelial Growth Factor Receptor (Fetal Liver Kinase 1 Monoclonal Antibody Inhibits Tumor Angiogenesis and Growth of Several Mouse and Human Tumors," Cancer Research, 59: 5209-5218, 1999
		Rubenstein et al., "Anti-VEGF Antibody Treatment of Glioblastoma Prolongs Survival But Results in Increased Vascular Cooption," Neoplasia, 2: 306-314, 2000
		Okada et al., "Impact of oncogenes in tumor angiogenesis: Mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells," Proc. Natl. Acad. Sci. USA, 95: 3609-3614, 1998
		Stacker et al., "VEGF-D promotes the metastatic spread of tumor cells via the lymphatics," Nature Medicine, 7: 186-191, 2001
EXAMINER		DATE CONSIDERED 11/17/04
* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		



Sheet 3 of 4


U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>	ATTY. DOCKET NO. 6460-41	APPLICATION NO. 07/075,433
	RECEIVED JAN 08 2003	
	APPLICANT Debinski et al.	GROUP TECH CENTER 1800/2900 1644

U.S. PATENT DOCUMENTS						
EXAMINER'S INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Park ↓		Zagzag et al., "Immunohistochemical Localization of Basic Fibroblast Growth Factor in Astrocytomas," Cancer Research, 50: 7393-7398, 1990
		Botelho et al., "Oncostatin M Stimulates c-Fos to Bind a Transcriptionally Responsive AP-1 Element within the Tissue Inhibitor of Metalloproteinase-1 Promoter," The Journal of Biological Chemistry, 273: 5211-5218, 1998
		Mohan et al., "Curcuminoids Inhibit the Angiogenic Response Stimulated by Fibroblast Growth Factor-2, Including Expression of Matrix Metalloproteinase Gelatinase B," The Journal of Biological Chemistry, 275: 10405-10412, 2000
		Nakano et al., "Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas," J. Neurosurg, 83: 298-307, 1995
		Millauer et al., "Glioblastoma growth inhibited <i>in vivo</i> by a dominant-negative Flk-1 mutant," Nature, 367: 576-579, 1994
		Takano et al., "Concentration of Vascular Endothelial Growth Factor in the Serum and Tumor Tissue of Brain Tumor Patients," Cancer Research, 56: 2185-2190, 1996
EXAMINER Park		DATE CONSIDERED 11/17/04
* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		



Sheet 1 of 1

Form PTO-100
(Rev. 2-88)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
6460-41APPLICATION NO.
10/075,823INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

APPLICANT
Debinski et al.FILING DATE
February 12, 2002

GROUP

1644

U.S. PATENT DOCUMENTS

EXAMINER'S INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Pnt		Debinski et al., "VEGF-D is an X-linked/AP-1 Regulated Putative Onco-angiogen in Human Glioblastoma Multiforme," Molecular Medicine, 7: 598-608, 2001
		Title et al., "Vascular Endothelial Growth factor (VEGF) Receptor-2 Antagonists Inhibit VEGF- and Basic Fibroblast Growth Factor-Induced Angiogenesis in Vivo and in Vitro," Journal Pharmacol. & Exp. Therapeutics, 299: 1073-1085, 2001
✓		

EXAMINER

DATE CONSIDERED

11/17/04

* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

NOV 08 2002

TECH CENTER 1600/2900